137 related articles for article (PubMed ID: 30169612)
1. Dysplasia severity is associated with poor quality of life in patients with Barrett's esophagus referred for endoscopic eradication therapy.
Han S; Yadlapati R; Simon V; Ezekwe E; Early DS; Kushnir V; Hollander T; Brauer BC; Hammad H; Edmundowicz SA; Wood M; Shaheen NJ; Muthusamy RV; Komanduri S; Wani S
Dis Esophagus; 2019 Jan; 32(1):. PubMed ID: 30169612
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
3. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study.
van Vilsteren FG; Alvarez Herrero L; Pouw RE; Schrijnders D; Sondermeijer CM; Bisschops R; Esteban JM; Meining A; Neuhaus H; Parra-Blanco A; Pech O; Ragunath K; Rembacken B; Schenk BE; Visser M; ten Kate FJ; Meijer SL; Reitsma JB; Weusten BL; Schoon EJ; Bergman JJ
Endoscopy; 2013 Jul; 45(7):516-25. PubMed ID: 23580412
[TBL] [Abstract][Full Text] [Related]
5. Perceptions of risk and therapy among patients with Barrett's esophagus: a patient survey study.
Stier MW; Lodhia N; Jacobs J; Nozicka D; Kavitt R; Siddiqui U; Waxman I; Konda VJ
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29036278
[TBL] [Abstract][Full Text] [Related]
6. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium.
Gopal DV; Lieberman DA; Magaret N; Fennerty MB; Sampliner RE; Garewal HS; Falk GW; Faigel DO
Dig Dis Sci; 2003 Aug; 48(8):1537-41. PubMed ID: 12924649
[TBL] [Abstract][Full Text] [Related]
8. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3420-6. PubMed ID: 10606297
[TBL] [Abstract][Full Text] [Related]
9. Persistent intestinal metaplasia after endoscopic eradication therapy of neoplastic Barrett's esophagus increases the risk of dysplasia recurrence: meta-analysis.
Sawas T; Alsawas M; Bazerbachi F; Iyer PG; Wang KK; Murad MH; Katzka DA
Gastrointest Endosc; 2019 May; 89(5):913-925.e6. PubMed ID: 30529044
[TBL] [Abstract][Full Text] [Related]
10. Quality of life and fear of cancer recurrence after endoscopic treatment for early Barrett's neoplasia: a prospective study.
Rosmolen WD; Nieuwkerk PT; Pouw RE; van Berge Henegouwen MI; Bergman JJ; Sprangers MA
Dis Esophagus; 2017 Feb; 30(3):1-9. PubMed ID: 27766707
[TBL] [Abstract][Full Text] [Related]
11. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
[TBL] [Abstract][Full Text] [Related]
12. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.
Levine DS; Haggitt RC; Blount PL; Rabinovitch PS; Rusch VW; Reid BJ
Gastroenterology; 1993 Jul; 105(1):40-50. PubMed ID: 8514061
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett's esophagus with low-grade dysplasia.
Kahn A; Al-Qaisi M; Kommineni VT; Callaway JK; Boroff ES; Burdick GE; Lam-Himlin DM; Temkit M; Vela MF; Ramirez FC
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29036431
[TBL] [Abstract][Full Text] [Related]
14. Radiofrequency ablation in Barrett's esophagus with dysplasia.
Shaheen NJ; Sharma P; Overholt BF; Wolfsen HC; Sampliner RE; Wang KK; Galanko JA; Bronner MP; Goldblum JR; Bennett AE; Jobe BA; Eisen GM; Fennerty MB; Hunter JG; Fleischer DE; Sharma VK; Hawes RH; Hoffman BJ; Rothstein RI; Gordon SR; Mashimo H; Chang KJ; Muthusamy VR; Edmundowicz SA; Spechler SJ; Siddiqui AA; Souza RF; Infantolino A; Falk GW; Kimmey MB; Madanick RD; Chak A; Lightdale CJ
N Engl J Med; 2009 May; 360(22):2277-88. PubMed ID: 19474425
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of Barrett's Esophagus is Rare Following Endoscopic Eradication Therapy Coupled With Effective Reflux Control.
Komanduri S; Kahrilas PJ; Krishnan K; McGorisk T; Bidari K; Grande D; Keefer L; Pandolfino J
Am J Gastroenterol; 2017 Apr; 112(4):556-566. PubMed ID: 28195178
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication.
Guarner-Argente C; Buoncristiano T; Furth EE; Falk GW; Ginsberg GG
Gastrointest Endosc; 2013 Feb; 77(2):190-9. PubMed ID: 23317687
[TBL] [Abstract][Full Text] [Related]
17. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
18. Controversies in Barrett's esophagus: management of high grade dysplasia.
Sharma P
Semin Gastrointest Dis; 2001 Jan; 12(1):26-32. PubMed ID: 11215852
[TBL] [Abstract][Full Text] [Related]
19. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
[TBL] [Abstract][Full Text] [Related]
20. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
